Related references
Note: Only part of the references are listed.Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis
Ariela Noy et al.
BLOOD ADVANCES (2020)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Ariela Noy et al.
BLOOD (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Share Paper
